# INCY: Incyte Genomics Inc

- Industry: Services-Commercial Physical & Biological Research
- Current price: $125.31
- Price updated: Sep 19, 2026
- Total congressional trades: 1
- Politicians trading: 1
- Last traded: May 15, 2025
- Source: https://tryglasshouse.ai/companies/INCY.md

Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes an array of oncology and dermatology programs.

# Congressional trading history

- Page: 1 of 1
- Results: 1 of 1
- Pagination query parameter: `page`

## 1. Robert Bresnahan

- Member: Republican, House
- Transaction: Sell, $1,001 - $15,000
- Dates: traded May 15, 2025, disclosed May 31, 2025
- Market context: $62.76 at trade, $125.31 current (+99.67%)
- Politician: https://tryglasshouse.ai/politicians/B001327.md
- Record: https://tryglasshouse.ai/trades/37e39509-d1cd-4401-91a4-b9754db19d81.md



Prices and percentage changes are market context, not portfolio returns. This information is not financial advice.